Arvinas has joined the Michael J. Fox Foundation's LITE and PPMI programs to support the development of ARV-102, an investigational drug targeting LRRK2 for Parkinson’s disease and related neurodegenerative disorders. This collaboration aims to enhance research on LRRK2 biology and accelerate clinical trials, including ongoing Phase 1 studies and planned Phase 1b and Phase 2 trials. Participation in these initiatives will help Arvinas leverage shared resources and data to improve therapeutic strategies and potentially benefit patients with Parkinson’s and progressive supranuclear palsy.
Sustainability LIVE: The London Summit 2026 will feature a panel titled 'The Future of Net Zero Automotive' on September 8-9, focusing on the automotive industry's efforts to achieve net zero emissions. Senior executives from Toyota Motor Europe, Con...
LanzaTech's joint venture, Beijing Shougang LanzaTech, launched an IPO on the Hong Kong Stock Exchange, raising approximately $75 million by offering 40 million H-Shares at about $1.86 each. The IPO values the JV at around $750 million and underscore...
Credit Benchmark has appointed Piers MacWhannell as its new Global Head of Partnerships to drive the company's global growth and expand its partnership ecosystem. MacWhannell brings 25 years of experience in financial markets and will focus on buildi...
Vivakor, Inc. announced a one-year crude oil transaction agreement through its trading platform, Vivakor Supply & Trading, involving about 100,000 barrels per month at the Cushing Terminal. This deal, effective from June 1, 2026, to May 31, 2027, is ...
Chinese carmaker Chery is cautiously entering Japan's auto market through a Singapore-based joint venture, planning to launch an electric 'kei' microcar in 2027. This move targets Japan's unique market dominated by domestic giants and characterized b...
